News | BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (BBOT) Granted U.S. FDA Fast Track Designation for BBO-8520 for KRAS^G12C-Mutated Metastatic Non-Small Cell Lung Cancer

January 9, 2025/in 2025, News/by Jake Robison

January 9, 2025

BridgeBio Oncology Therapeutics (BBOT) to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

December 23, 2024/in 2024, News/by Jake Robison

December 23, 2024

BBO-8520 Preclinical Data Published in Cancer Discovery Supports the Potential for the First-in-Class Molecule to Provide Therapeutic Benefit in KRAS^G12C Mutant Tumors

December 9, 2024/in 2024, News/by Jake Robison

December 9, 2024

BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director

November 15, 2024/in 2024, News/by eallison

November 18, 2024

BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors

October 31, 2024/in 2024, News/by David Anderson

October 30, 2024

BridgeBio Oncology Therapeutics (BBOT) Announces the Appointment of Yong Ben, MD, as Chief Medical and Development Officer

September 6, 2024/in 2024, News/by eallison

September 9, 2024

BridgeBio Oncology Therapeutics announces first patient dosed with BBO-8520 in the Ph. 1 ONKORAS-101 trial for KRAS^G12C NSCLC

June 6, 2024/in 2024, News/by eallison

June 6, 2024

BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

May 2, 2024/in 2024, News/by eallison

May 2, 2024